Runben Shares released its 2026 interim report, with net profit attributable to the parent company of 225 million yuan, up 20.03% from the same period last year. Total operating revenue was 1.054 billion yuan, up 17.74% year-on-year, marking four consecutive years of growth. Net cash inflow from operating activities was 189 million yuan, up 41.38% year-on-year. The company's latest gross margin was 60.52%, up 1.42 percentage points from the previous quarter, achieving five consecutive quarters of increase. The latest return on equity was 9.62%, up 0.99 percentage points year-on-year. Diluted earnings per share were 0.56 yuan, up 21.74% year-on-year.
Runben Biotechnology Co Ltd Ordinary Shares - Class AInterim net profit up 20.03% and revenue up 17.74%, with improved margins and ROE.